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Abstract
Progress in the management of patients with myelodysplastic syndromes (MDS) has been 
hampered by the inability to detect cytogenetic abnormalities in 40-60% of cases. We 
prospectively analyzed matched pairs of bone marrow and buccal cell (normal) DNA samples 
from 51 MDS patients by single nucleotide polymorphism (SNP) arrays, and identified 
somatically acquired clonal genomic abnormalities in 21 patients (41%). Among the 33 patients 
with normal bone marrow cell karyotypes, five (15%) had clonal, somatically acquired aberrations 
by SNP array analysis, including four with segmental uniparental disomies (UPD) and one with 
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three separate microdeletions. Each abnormality was detected more readily in CD34+ cells then in 
unselected bone marrow cells. Paired analysis of bone marrow and buccal cell DNA from each 
patient was necessary to distinguish true clonal genomic abnormalities from inherited copy 
number variations and regions with apparent LOH. UPDs affecting chromosome 7q were 
identified in two patients who had a rapidly deteriorating clinical course despite a low-risk 
International Prognostic Scoring System score (IPSS). Further studies of larger numbers of 
patients will be needed to determine whether 7q UPD detected by SNP array analysis will identify 
higher-risk MDS patients at diagnosis, analogous to those with 7q cytogenetic abnormalities.
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Myelodysplastic Syndrome; SNP array; Uniparental Disomy
Introduction
The myelodysplastic syndromes (MDS) are predominantly diseases of the elderly (median 
age at diagnosis, 70 years) and are among the most common hematologic malignancies, 
affecting 1 in 500 persons over 65 years of age (1-3). Patients present with cytopenias 
involving one or more blood cell lineages, bone marrow morphologic findings indicative of 
mono-, di- or tri-lineage dysplasia, and a variable risk of transformation to acute leukemia. 
Currently, allogeneic stem cell transplantation offers the only curative therapy for MDS (4), 
but is not a realistic option for most elderly patients.
Cases of MDS are thought to arise from the clonal acquisition of mutations in multipotent 
hematopoietic stem cells, but the precise molecular abnormalities remain poorly defined. 
Bone marrow cytogenetic studies are helpful in this regard, revealing clonal abnormalities in 
30 to 50% of cases, most frequently deletions of chromosomes 5, 7, and 20 and/or trisomy 8 
(5). Cases with del(5q) as the sole abnormality, the so-called 5q syndrome, have shown 
remarkable responses to lenalidomide (6), and haploinsufficiency for the ribosomal protein 
14 (RPS14) gene appears to account for many of the clinical features of this syndrome (7). 
This suggests that improved detection of clonal genomic aberrations in MDS could identify 
additional patients likely to respond well to lenalidomide or perhaps to DNA 
methyltransferase inhibitors, such as 5-azacitidine and decitabine (8, 9). However, this 
leaves an estimated 50 to 70% of cases with normal bone marrow cell karyotypes for whom 
there are no molecular tests that could be used to distinguish between MDS and benign bone 
marrow cell diseases.
Recent studies of human cancers have indicated that small regions of specific clonal 
genomic abnormalities can be detected with high-density single nucleotide polymorphism 
(SNP) arrays, which provide a detailed structural examination of the cancer genome, 
including high-resolution analysis for loss of heterozygosity (LOH) (10). Two groups have 
applied this technology to the study of archival bone marrow samples from MDS patients, 
reporting a high frequency of detection of uniparental disomy (UPD) and copy number 
alterations, even in cases with a normal karyotype (11-15). We were troubled by these 
reports, because the MDS bone marrow samples were analyzed without a paired buccal or 
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other normal sample from the same patient. Instead, results were compared with those 
obtained from the blood cells of unrelated normal individuals. Without a paired analysis of 
bone marrow DNA with normal control DNA for each patient, we suspected that inherited 
copy number variations (CNVs) and genomic regions with apparent homozygosity due to 
linkage disequilibrium or consanguinity might confound the detection of somatically 
acquired abnormalities linked to the pathogenesis of the malignant clone. Thus, we 
undertook a prospective study of adults with MDS in which SNP array findings from bone 
marrow cell DNA were compared with those from matched control normal DNA extracted 
from autologous buccal swabs. We identified unambiguous, somatically acquired 
abnormalities with this approach in patients whose bone marrow cells had a normal 
karyotype, although at a lower frequency than has been previously reported (11-15). 
Importantly, we found that paired analysis of bone marrow and normal (buccal) DNA from 
each patient was necessary to distinguish acquired clonal abnormalities from inherited 
genomic variations.
Materials and Methods
Patients and clinical samples
Fifty-one patients were consecutively enrolled in this study seen at M.D. Anderson Cancer 
Center (MDACC) for a diagnosis and classification of MDS according to the WHO, FAB 
and IPSS systems (16-18) from June 21, 2006 to August 8, 2007. Patient characteristics are 
reported in Table 1 and Supplementary Tables 1 and 2. Buccal swabs and bone marrow 
aspirates were obtained with informed consent. Mononuclear cells were isolated from bone 
marrow aspirates by Ficoll centrifugation, and when sufficient cells were available, two 
thirds of these cells were further purified by magnetic beads (Milentyi) to obtain the CD34+ 
fraction. Cells were lysed in Gentra Puregene buffer (Qiagen). DNA from buccal swabs and 
the bone marrow cell lysates were prepared with the Gentra Puregene kit (Qiagen) and 
analyzed by spectrometry (Nanodrop Technologies).
SNP array analysis
Mononuclear bone marrow cell DNA and matched normal DNA from all 51 patients, 
together with the DNA from CD34+ bone marrow cells from 24 of these patients, was 
analyzed with Genechip Mapping 250K StyI arrays according to the manufacturer's protocol 
(Affymetrix). The data were analyzed with dChip (version August 5, 2008) (19). Raw data 
were normalized and modeled (PM/MM difference). Copy number values were computed 
by the “batch normalization” and “scaling copy number mode to 2 copies” algorithms. The 
raw data were inferred by the “median smoothing” algorithm and a window of 10 SNPs. To 
obtain standardized intensities (copy number values) across all probe sets, the log2 ratio was 
computed as log2 (signal intensity/mean signal intensity of all normal samples for a given 
SNP probe set). As a quality control, the standard deviation of the raw log2 ratio for each 
SNP probe set minus the raw log2 ratio for the adjacent SNP probe set was calculated along 
chr 1. Only samples with a standard deviation of 0.6 or smaller were included in the 
analysis. Reported segements of deletion or amplification (Supplementary Tables 1-3) were 
obtained by the Hidden Markov Model algorithm using a step of 0.2 and a standard 
deviation of 0.4. Only regions with a coverage of at least 5 consecutive probe sets, an 
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absolute average value of 0.2 and visual confirmation are reported. To identify CNVs, each 
matched normal sample was analyzed in the same way. LOH was inferred by the Hidden 
Markov Model. The LOH analysis for each patient was based on the comparison with the 
matched normal DNA. Only segments with an LOH probability greater then 0.8 were 
considered as LOH. UPDs were identified as copy-neutral LOH by comparison with the 
results of the copy number analysis. In addition to the LOH probability criterion, a UPD 
regions had to have at least 6 LOH calls (all LOH calls minus all conflict calls within that 
region) to be reported. As a third criterion, regions containing less than 5% informative calls 
were disregarded. Intervening segments of apparent retention were considered as LOH by 
comparison to their copy number status or if the number of calls was less then 6 (all 
retention calls minus all conflict calls within the segment). For the unpaired analysis all 
normal samples were disregarded. Instead, a reference genotype file containing 60 normal 
controls from the CEPH subset of the HapMap project (20) was used for the LOH analysis. 
All other parameters remained unchanged. Since no individual comparative calls are 
generated, the threshold for a region to be considered was set to at least 50 probe sets 
(SNPs) and at least 2 Mb in size.
Results
High Frequency of Deletions in MDS patients
We analyzed bone marrow samples from 51 patients with newly diagnosed MDS using 
high-resolution SNP arrays. Their median age was 66 years (range, 43 to 83 years) and 32 of 
51 (63%) had lower-risk disease (low or intermediate-1 IPSS scores). Thirty-three (65%) 
had normal karyotypes by conventional cytogenetic analysis. The distributions of patients by 
WHO, FAB and IPSS classifications are given in Table 1. For each patient, we compared 
the SNP array profiles of bone marrow mononuclear cell DNA with those of matched buccal 
swab DNA to detect somatically acquired clonal abnormalities of copy number as well as 
regions of LOH. Because MDS originates in hematopoietic stem cells, we also selected 
CD34+ cells from bone marrow aspirates of 24 patients and compared the SNP profiles with 
those of matched bone marrow mononuclear and buccal cells.
DNA copy number analysis identified chromosomal defects, mainly deletions, in 21 (41%) 
of the 51 patients (Supplementary Fig. 1, also Supplementary Tables 1 and 2). Chromosomal 
gains were less frequent than deletions and were found only in MDS cases with complex 
karyotypes (Supplementary Table 2). The most frequently deleted region (18% of all cases) 
was located on chromosome 5q, as is typical of cytogenetic findings in MDS(5). 
Heterozygous deletions were identified in eight patients (16%), together with a focal 
homozygous deletion of about 5 Mb within the 5q deleted region of patient 27 (Fig. 1, lanes 
22-24). By conventional karyotyping, this case had both a del(5q) and a t(5;12)(q33;q12) 
translocation, accounting for the deletion. Although the homozygously deleted region is 
located outside the two previously defined critical deleted regions (CDRs) on chromosome 
5q(21-23), half of our cases had a del(5q) that extended to the telomere, thus including the 5 
Mb homozygously deleted region.
Examples of recurrent chromosomal gain were also found in this cohort. Two patients (27 
and 49) had small regions of gain on chromosome 8 (Supplementary Fig. 3) that commonly 
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encompassed the 8q24.13-21 locus, which harbors the MYC gene. Four others (patients 34, 
37, 46 and 51) had 11q23 gains in association with multiple complex cytogenetic 
abnormalities, similar to the findings of others (24, 25).
Among the 24 patients with available CD34+ cell DNA, 11 (42%) had detectable 
chromosomal abnormalities by SNP array analysis. In most of these cases, the same 
aberrations were more readily detected in the purified CD34+ cells than in mononuclear 
bone marrow cells (see, for example, Fig.1, lanes 11 vs. 12, 14 vs. 15, 17 vs. 18 and 23 vs. 
24), consistent with the origin of MDS in hematopoietic stem cells. Thus, residual normal 
cells were present in the whole bone marrow mononuclear fractions of MDS patients. A 
significant fraction of these residual normal cells appeared to be mature T lymphocytes 
included in the unfractionated bone marrow mononuclear cells, as deletions of the T-cell 
receptor alpha locus (14q11.2) were detected in the bone marrow mononuclear cells of some 
cases, but not in either the matched CD34+ cell DNA or the buccal cell DNA 
(Supplementary Fig. 2). Buccal scrapings from some patients contained a small fraction of 
clonal blood leukocytes, resulting in a slightly lower-than-expected copy number for the 
region that was hemizygously deleted in the malignant clone (see, for example, patient 46 in 
Fig.1, lane 13). Relatively large regions of copy number gain were also observed at the 
proximal boundaries of some of the deletions (patients 37 and 46; Fig. 1, lanes 11, 12, 14 
and 15).
Clonal Abnormalities in Patients with a Normal Bone Marrow Cell Karyotype
Comparison of DNA genotyping profiles for bone marrow versus buccal cells from each 
patient identified clonal regions of acquired, copy-neutral LOH (indicative of acquired 
segmental regions of uniparental disomy, UPD) in MDS bone marrow cells of four of 33 
(12%) patients with a normal bone marrow cell karyotype (Figs. 2 and 4). In addition, one 
(patient 34) with a complex karyotype and one (patient 19) with a t(11,19) translocation had 
UPDs. The UPDs were found within segments of 3q (patient 15), 4q (patients 19 and 48), 7q 
(patients 5 and 7) and 17p (patient 34) and entirely extended to the telomere, suggesting that 
they resulted from a single recombination event per chromosome, possibly involving break-
induced replication (BIR) (26). Monosomy 7 and del(7q) are established poor-risk 
cytogenetic findings in the bone marrow cells of MDS patients (17); hence, our detection of 
7q UPDs spanning the same critical region in two of 33 cases with a normal karyotype 
indicates that approximately 6% of patients (90% confidence interval 1% to 18%) who lack 
other high-risk chromosomal features may harbor defects affecting this critical region of 
chromosome 7q. Patient 26 had a normal bone marrow cell karyotype by standard 
cytogenetic analysis, but SNP profiling revealed three small heterozygous deletions (Fig. 3) 
at 6q21 (3 Mb), 12p13.2 (1.5 Mb) and 21q22.12 (1.2 Mb). The 21q22.12 region contains the 
RUNX1 gene, and the deletion breakpoint was located within that locus. Alternatively, a 
cryptic translocation with an accompanying deletion of a small region could have led to the 
disruption of the intact RUNX1 locus in this patient. Another patient (49) also showed a 
disruption of the RUNX1 locus by a very small deletion, which was detected in the context 
of other abnormalities discernible by standard karyotyping. RUNX1 encodes a critical 
regulator of hematopoietic differentiation and can be inactivated by mutation or 
translocation in both MDS and AML (27, 28). Thus, SNP array analysis can pinpoint small 
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regions of deletion that harbor tumor suppressor genes, such as RUNX1, which are often 
mutated in MDS.
Association of UPD 7q with a Deteriorating Clinical Course
The short follow-up times for this study group precluded a statistical analysis of the 
association between SNP array findings and the clinical outcome of therapy. Within the 
normal karyotype subgroup (n=33), however, we noted that the two patients identified as 
having UPDs affecting the long arm of chromosome 7 (Fig. 4) experienced a deteriorating 
clinical course. One patient (no. 5) was a 56-year-old woman with refractory anemia and an 
IPSS score of zero who had a UPD at 7q22.1-7qtel at presentation. Over the next 10 months, 
she developed rapidly increasing bone marrow blast counts and worsening cytopenias and 
died. The other patient (no. 7) was a 67-year-old man with refractory anemia and a 
hypercellular bone marrow showing multilineage dysplasia and an IPSS score of zero. At 
presentation he had a UPD at 7q31.33-7qtel. Over the next 12 months, he developed 
thrombocytopenia, leukocytosis and pleural effusions, and died. The finding of a 
chromosome 7 cytogenetic abnormality in MDS confers a higher-risk score according to the 
IPSS criteria (17). In these two patients with normal bone marrow cell karyotypes, our 
results suggest that UPD 7q detected by SNP array may identify the same subset of higher 
risk patients as does a cytogenetic abnormality of chromosome 7 (Fig. 4).
Requirement for Matched Normal DNA in SNP Array Analysis
The human genome contains structural variations consisting of thousands of regions in 
which segments of DNA have been gained or lost. These so-called copy number variations, 
or CNVs, constitute much of the inherited variation among individuals (29-31). A growing 
number of the most frequently occurring CNVs have been cataloged in databases (32), and 
must be considered in the interpretation of SNP array results; however, additional CNVs 
occur at low frequency in human populations and have not yet been included in existing 
databases.
Published SNP array analyses of bone marrow cells from MDS patients (11-15) have relied 
mainly on CNV databases and DNA samples from unrelated individuals, rather than on 
paired samples of normal DNA for each patient, to substantiate regions of MDS-related 
copy number aberrations or UPD. This method can yield spurious results, as low allelic 
frequencies of inherited CNVs and linkage disequilibrium in the inheritance of linked SNPs 
can often mimic small regions of deletion or gain, as well as acquired UPDs, in an unpaired 
analysis. Thus, we reanalyzed the SNP array data from our patient cohort with normal bone 
marrow cell karyotypes (n=33) to determine the proportion of inherited polymorphisms and 
CNVs that would be erroneously identified as clonal, somatically acquired genomic 
abnormalities without the use of individual normal controls. By this approach, we identified 
31 non-redundant copy number changes, mainly deletions, in 27 of the patients; their sizes 
ranged from 0.4 to 1897 kb (minimal coverage 5 consecutive SNPs). Analysis with paired 
normal DNA samples revealed that only 3 of these lesions were true microdeletions, 
whereas 28 were CNVs. Even upon reconciliation with a CNV database (32), 6 (21%) of the 
28 CNVs we identified would have been falsely identified as microdeletions. Figure 5A 
shows examples of 3 CNVs that each occurred only once in the analysis of the 33 patients 
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with a normal karyotype. Each of these areas of copy number loss is readily apparent in both 
the DNA from bone marrow and the paired buccal swab from the same patient, clearly 
indicating that they are all inherited CNVs. By contrast, the region of copy number loss 
identified in the bone marrow cells of patient 26 is not present in the matched buccal DNA 
sample, identifing this region as a somatically acquired microdeletion. Thus, matched 
normal controls are needed to reliably detect true copy number alterations.
Similarly, reanalysis of our LOH results, replacing the matched normal DNA samples with 
60 unrelated normal controls (CEPH subset of the HapMap project (20)) identified 110 
regions of potential LOH in the 33 patients with a normal karyotype (regions covered by 
more than 50 SNPs and greater than 2 Mb in size). With use of matched buccal DNA 
samples, however, we were able to show that only 4 (3.6%) of these 110 regions represented 
true UPDs. An example of the detection of a true UPD is shown in Figure 5B, in which a 
large region of chromosome 7q exhibits LOH based on the SNP calls, with retention of 
normal copy number by comparison of bone marrow and matched normal DNA. By 
contrast, a region of 12.2 Mb in patient 2 shows apparent LOH based on analysis of 60 
unrelated normal controls (Fig. 5C, unpaired). However, analysis of the same patient's bone 
marrow DNA compared with the matched normal DNA (Fig. 5C, paired) reveals that this 
region is actually a stretch of apparent homozygosity (only A or B calls), which is 
maintained in both the normal and the bone marrow DNA of this patient and does not 
represent a somatically acquired loss and reduplication event leading to UPD (see 
Supplementary Fig. 4 for an additional example). Thus, failure to include paired normal 
DNA samples in SNP array analysis of bone marrow cells from MDS patients can lead to 
vastly overestimated frequencies of UPDs and microdeletions, most of which are not linked 
to somatic abnormalities that have occurred during the genesis of the MDS clone.
Discussion
This prospective study, the first to apply genome-wide SNP array analysis to paired bone 
marrow and normal DNA specimens from a large cohort of patients with MDS, identified 
cryptic chromosomal changes with both clinical and molecular genetic implications. Our 
findings differ in important aspects from those in retrospective studies based on DNA 
extracted from archived bone marrow cell samples (11-15). Importantly, the overall rate of 
genomic abnormalities in MDS patients with normal bone marrow karyotypes was much 
lower in our analysis than in earlier studies. We attribute this discrepancy to the lack of 
paired normal DNA samples in most previous analyses resulting in the spurious 
identification of inherited CNVs or regions of apparent homozygosity as somatically 
acquired genomic alterations within the MDS clone. Indeed, we demonstrate that the 
majority of apparent abnormalities detected by analysis of bone marrow cell DNA alone 
reflect inherited genomic diversity rather than clonal somatic abnormalities. Thus, a 
straightforward comparison with matched normal DNA is required to identify unequivocally 
the more subtle aberrations arising from acquired clonal genomic changes. Hence, an 
attempt to correlate UPD or copy number changes with clinical outcome (14, 15) in patients 
who have been incorrectly classified due to uncontrolled assessment of genomic variation 
will not yield valid results.
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Aside from its role in assessing bone marrow cell clonality in newly diagnosed cases of 
MDS, SNP array analysis promises to help unravel the molecular pathogenesis of these 
complex stem cell diseases. Indeed, identification of discrete clonal molecular changes in 
MDS by high-density SNP array analysis will likely provide the best starting point for the 
discovery of new genetic mutations and signal transduction pathways involved in MDS, 
leading to the development of more effective targeted therapies. We would emphasize that 
the smallest regions of copy number alteration or LOH are often the most informative in 
implicating individual genes for detailed sequence analysis, but these small regions are also 
the most difficult to distinguish from nonpathologic human germline variations. Hence, 
consistent use of paired bone marrow and normal DNA samples would also be expected to 
accelerate the pace of disease allele discovery in MDS.
We also addressed the question of whether CD34+ cell selection is required to assess the 
clonal aberrations in MDS. All of the aberrations found in the CD34+ fraction were also 
identified in unselected mononuclear cells, indicating that the clonality of the MDS bone 
marrow is remarkably high. Our results suggest that the cells lacking MDS-associated clonal 
changes in the bone marrow-derived samples are mainly circulating blood T-lymphocytes 
(see Supplementary Fig. 2), indicating that depletion of mature T cells might be a useful 
strategy for removing residual normal cells from the bone marrow aspirate. In any event, 
SNP array analysis in MDS can be performed with the mononuclear fraction of whole bone 
marrow cells, and is therefore clinically feasible even when, as is often the case, the MDS 
bone marrow sample contains low numbers of cells.
We report the identification of UPDs in four of 33 patients with a normal karyotype. 
Notably, all segmental UPDs discovered in this study were terminal (see Supplementary Fig.
5 for summary). This suggests that break-induced replication (BIR (26)) might be a 
dominant mechanism by which a cell duplicates a somatically acquired event such as a 
mutation, a microdeletion or an epigenetically suppressed region and consequently become 
homozygous for this segmental region. BIR appears to be a common repair mechanism at 
stalled or broken replication forks, however, only the reduplication of a region that contains 
a genetic or epigenetic alteration conferring a growth advantage to the cell would allow for 
its clonal dominance and selection, leading to its detection by LOH analysis. In this regard, 
our findings of nonrandom segmental UPDs help to clarify models purporting to explain the 
pathogenetic basis of large deletions that are typically observed in MDS cases. Certain large 
deletions, such as the del(5q), are thought to arise from haploinsufficiency for one or more 
genes within the targeted regions (21, 23). Indeed, haploinsufficiency for the RPS14 gene 
has recently been linked to the pathogenesis of MDS associated with the 5q- syndrome(7); 
homozygous inactivation is not observed in such cases because the RPS14 protein is 
essential for cellular protein synthesis. Consistent with this model of molecular 
pathogenesis, we did not observe any UPD affecting 5q in MDS cases. Apparently, deletion 
of one allele of 5q is sufficient for pathogenesis, and loss of the wild-type alleles with 
reduplication of mutated or microdeleted target genes on 5q, as would occur with a UPD, is 
strongly selected against, because it is lethal to the MDS stem cell. By contrast, we did 
observe UPD affecting the same deleted region that is affected in cases with cytogenetically 
apparent loss of the long arm of chromosome 7. This implies that at least one mutated or 
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epigenetically suppressed gene in this region is likely reduplicated together with loss of the 
normal allele in cases with 7q UPD, fulfilling Knudsen's hypothesis for the homozygous 
inactivation of classical tumor suppressor genes (33).
We hypothesize that genes within the region of UPD on chromosome 7 are likely to harbor 
inactivating point mutations that will eventually be identified by judicious sequencing of the 
involved genes in specific cases with UPD. By contrast, other regions of UPD that do not 
correspond to regions of cytogenetic deletion may harbor activating mutations that are 
duplicated by UPD and thus provide a growth advantage (34). FLT3 mutations in acute 
myeloid leukemia (AML) fit the latter category, in that they are frequently identified on both 
alleles in AML cases with a normal karyotype. Thus, SNP array analysis can provide critical 
information needed to pinpoint and identify mutated genes and altered signal transduction 
pathways in MDS.
A major goal of our study was to detect clonal genomic abnormalities in MDS patients that 
could be used to improve the clinical management of these disorders. Although longer 
follow-up times are needed to determine the association of our SNP array findings with 
treatment outcome, several results appear to have immediate relevance to patient 
management. The ability to detect clonal genomic aberrations in cases with a normal bone 
marrow cell karyotype using SNP array analysis can distinguish MDS from other causes of 
bone marrow cell dysplasia and pancytopenia due to the effects of drugs, environmental 
toxins or aberrant immune responses, thus aiding in the initial diagnosis. Moreover, our 
identification of UPDs affecting chromosome 7 in two patients with low-risk IPSS scores 
who later showed rapidly deteriorating clinical courses is intriguing. UPD selects for 
homozygosity of a specific genomic region, and the same region of chromosome 7q affected 
by UPD is also very often deleted in MDS cases. When identified by cytogenetic analysis, 
abnormalities of chromosome 7q by themselves signify an increased IPSS score. Thus, it is 
possible that the 7q UPDs we identified are equivalent to a deletion in this region and may 
constitute a high-risk feature in MDS (17). Whether or not UPDs affecting this and other 
genomic regions convey important prognostic information is an important question to 
address in additional prospective studies using SNP array technology to evaluate patients 
with MDS entering clinical therapeutic trials.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Copy number alterations on chromosome 5
The copy number values for probe sets on chromosome 5 are shown as log2 ratios. Patients 
with abnormalities affecting this chromosome are identified at the top of each column 
together with the DNA source (N, normal cells; WBM, whole bone marrow mononuclear 
cells; CD34, CD34+ bone marrow cells). White areas indicate no copy number change (log2 
ratio = zero), while shades of blue and red designate losses and gains, respectively (see scale 
at bottom). All blue areas on the q-arm correspond to heterozygous deletions, except in 
patient 27, where a homozygously deleted area (dark blue) was found within the 
heterozygous region of loss. A profile view of the copy number for this patient is shown on 
the right. The red line indicates the expected normal copy number, while the blue line 
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indicates the log2 ratio of the measured copy number along the chromosome. The positions 
of the two previously described common deleted regions (CDRs) of chromosome 5q are 
indicated.
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Figure 2. Uniparental disomies in cases with a normal bone marrow cell karyotype
Copy number analysis and paired genotype (LOH) analysis are shown for patients 15, 19 
and 48, as indicated at the top of each column together with the DNA source (N, normal 
cells; WBM, whole bone marrow mononuclear cells). Only informative chromosomes are 
shown; all remaining chromosomal regions were normal by copy number and LOH analysis. 
The finding of LOH with a normal copy number reveals the presence of segmental UPD in 
these patients.
Heinrichs et al. Page 14
Leukemia. Author manuscript; available in PMC 2010 October 06.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. Small deletions identified in patients 26 and 49
Copy number values along chromosomes 6 and 12 (patient 26) and 21 (patient 26 and 49) 
are shown as log2 ratios. Patient identifiers are designated at the top of each column, 
together with the DNA source (N, normal cells; WBM, whole bone marrow mononuclear 
cells). The blue arrows indicate the loci of deletions. On chromosome 21, the arrows 
indicate the locus of the RUNX1 gene, which is affected by a deletion distal to the 
centromere in patient 26 and proximal in patient 49. Chromosomes are not drawn to scale.
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Figure 4. Uniparental disomies and copy number alterations on chromosome 7
Copy number values along chromosome 7 are shown as log2 ratios for all patients having a 
copy number change on this chromosome and for patients 6 and 8, who lack a copy number 
change. Patient identifiers are included at the top of each column together with the DNA 
source (N, normal cells; WBM, whole bone marrow mononuclear cells). Two additional 
plots (for patients 5 and 7) show the results of a paired genotype analysis (LOH analysis), 
which is based on the comparison of mononuclear cell DNA with matched DNA. Yellow 
areas indicate retention of the genotype, while blue areas indicate LOH. In patients 5 and 7, 
the finding of LOH extending to the telomere of the long arm of chromosome 7 with a 
normal copy number is caused by segmental UPD (see text).
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Figure 5. 
A: Comparison of CNV loci and mircrodeletions. The copy number values are shown as 
log 2 ratios at high magnification. Different chromosomes are not drawn to the same scale. 
Patients are identified at the top of each column together with the DNA source (N, normal 
cells; WBM, whole bone marrow mononuclear cells). The comparative analysis of copy 
number values with a match normal allows the differentiation of CNVs (left panel) and 
microdeletions (right panel). CNVs and microdeletions shown here explamplify findings 
summarized in Supplementary Table 1 and 3. B/C: Detection of true UPDs in paired 
samples as opposed to findings by unpaired LOH analysis. The results of copy number 
analysis are shown in the columns labeled “1”and reveal no deletions or gains. The raw 
genotyping calls are depicted in columns labeled “2” (A in red, B in blue, AB in yellow). 
The inferred LOH analysis (column 3; yellow signifies retention and blue LOH, 
respectively) is the result of the comparative genotype analysis. In cases of unpaired 
analysis, 60 normal controls (not shown) were used (CEPH subset of the HapMap project). 
Planel B illustrates the detection of a true UPD on chromosome 7p in patient 5. Planel C: 
Detection of a 12Mb locus with apparent UPD by unpaired analysis in patient 2, that is 
reveal as strech of inherited homozygosity by paired analysis. The comparison between left 
and right part of panel C emphasizes the necessity of paired analysis.
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Table 1
Characteristics of the patient cohort (n=51)*
Median Age (range) 66 (43-83)
number percentage
Cytogenetics normal karyotype 33 64.7
aberrant karyotype 18 35.3
Sex female 20 39.2
male 31 60.8
WHO classification RA 4 7.8
RCMD 7 13.7
RARS 1 2.0
RCDM-RS 4 7.8
RAEB-1 11 21.6
RAEB-2 13 25.5
unclassified 11 21.6
FAB classification RA 15 29.4
RARS 5 9.8
RAEB 21 41.2
RAEB-t 5 9.8
CMML 3 5.9
AML evolved from MDS 2 3.9
IPSS 0 Low risk 12 23.5
0.5-1.0 Intermediate 1 20 39.2
1.5-2.0 Intermediate 2 13 25.5
>2.0 High 5 9.8
AML evolved from MDS 1 2.0
*
see Supplementary Tables 1 and 2 for patient-by-patient characteristics and results
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